- Donate
- Understanding Rare Disease
- Living with a Rare Disease
- Community Support
- Advancing Research
- Driving Policy
- Get Involved
- Rare Disease News
- Resource Library
- About Us
- For Clinicians & Researchers
- For Patient Organizations
Last updated: March 24, 2020
Years published: 1989, 1992, 1993, 1994, 1996, 2004, 2008, 2020
NORD gratefully acknowledges Mario Melika, NORD Editorial Intern from the Massachusetts College of Pharmacy and Health Sciences, and Stephen G. Kaler, MD, CAPT, US Public Health Service (Ret), Professor of Pediatrics and Genetics, The Ohio State University College of Medicine, Center for Gene Therapy; Abigail Wexner Research Institute, Nationwide Childrenโs Hospital, for assistance eon the preparation of this report.
Introduction
Menkes disease (MD) is an inherited X-linked recessive disorder that affects many systems in the body. Affected infants are often born prematurely and may have non-specific symptoms such as hypothermia, hypoglycemia, and prolonged jaundice. One obvious and specific physical sign is โsteelyโ or โkinkyโ hair that usually develops by several months of age. Menkes disease is also associated with seizures, stunted growth, failure to thrive, unstable body temperature, and intellectual disability.
Menkes disease is caused by mutations in the ATP7A gene that is responsible for transport of copper throughout the body. The body uses copper as a cofactor to activate certain enzymes in order to carry out certain functions. When these enzymes are not working normally, serious and fatal effects can ensue over time related to the function of the copper-dependent enzymes that control the development of hair, brain, bones, liver, and arteries. Variants of MD that are caused by mutations in the ATP7A gene but result in less severe symptoms include mild Menkes disease and occipital horn syndrome.
There is no complete cure for Menkes disease at this time, but treatment with parenteral copper histidinate (CuHis) can increase survival and lessen the neurological symptoms if initiated early, within approximately 28 days following birth.
Menkes disease is characterized by dry skin and abnormal hair that is often brittle, tangled, sparse, steely or kinky and is often white, ivory, or grey in color. The affected infant may also appear to have a yellow appearance (jaundice) which is caused by excessive bilirubin in the blood (hyperbilirubinemia). Lower than normal body temperature (hypothermia) also may occur in the neonatal period. The normal, asymptomatic phase of the illness typically lasts for two to three months.
Brain and cognitive abnormalities are central in this disorder. Blood clots (subdural hematomas) and/or rupture or thrombosis of arteries in the brain may occur. Neurodegenerative effects such as seizures, and delayed growth and development may also arise. Reduced bone density (osteoporosis) is common and may result in fractures. The combination of subdural hematoma and bone fractures may lead to an incorrect diagnosis of child abuse. Emphysema, bladder diverticula, neck masses due to internal jugular vein phlebectasia, and cortical blindness have also been described.
Occipital horn syndrome (OHS) is recognized as a milder form of MD with less severe neurological involvement and is usually diagnosed around the age of 5-10 years.
Menkes disease is an X-linked genetic disorder caused by mutations in the ATP7A gene. This gene is responsible for production of the ATPase enzyme that regulates copper levels in the body. Individuals with Menkes disease have an abnormally low level of copper in the brain and liver and excess copper in the intestines and kidneys. Without the copper as a key element in their structure and functioning, the activity of the bodyโs copper-dependent enzymes is diminished. For example, reduced activity of the cuproenzyme tyrosinase causes reduced pigmentation of the hair and skin. Reduced activity of the cuproenzyme lysine oxidase causes failure of connective tissue to form strong, inner blood vessels walls.
X-linked genetic disorders are conditions caused by a non-working gene on the X chromosome and manifest in males. Females that have a non-working gene present on one of their X chromosomes are carriers for that disorder. Carrier females usually do not display symptoms because females have two X chromosomes and only one carries the non-working gene. However, since males have one X chromosome, inherited from the mother, if a male inherits an X chromosome harboring a non-working gene, he will develop the disease.
Female carriers of an X-linked disorder have a 50% chance to have a son affected with the disease and a 50% chance of an unaffected son. There is a 50% chance with each pregnancy to have asymptomatic โcarrierโ daughter like themselves, and a 50% chance to have a non-carrier daughter.
If a male with an X-linked disorder is able to reproduce, he will pass the non-working gene to all of his daughters who will be carriers. A male cannot pass an X-linked gene to his sons because males always pass their Y chromosome instead of their X chromosome to male offspring.
Recent studies suggest that the incidence of Menkes disease is about 1 in 35,000 live male births. The majority of diagnosed infants are male; however, MD may still occur in females, related to unusual genetic circumstances.
The diagnosis of MD is suggested by the appearance of brittle, tangled, sparse, steely or kinky hair at several months of age. Blood tests showing low levels of serum copper and ceruloplasmin support the diagnosis. It is important to note that these levels are typically low in otherwise healthy newborns. A new method of diagnosis that can potential identify affected infants before copper deficiency affects the brain involves measurement of plasma catecholamine levels. This may be the basis for Menkes disease newborn screening in the future. Molecular genetic testing for mutations in the ATP7A gene may also prove to be an efficient method of population-based newborn screening.
For infants suspected to be affected on clinical and biochemical grounds, ATP7A mutation testing is available commercially to confirm the diagnosis. Carrier testing and prenatal diagnosis are also available once a specific ATP7A gene variant has been identified in an affected family member.
Treatment
Early (ideally within 28 days of age of birth, corrected for prematurity) treatment of Menkes disease is essential. Injections of a copper histidinate (CuHis), a new molecular entity prepared as a freeze-dried product, have been shown to increase the concentration of copper in the blood and improve neurodevelopmental outcomes in some patients. The degree of CuHis treatment efficacy in older, symptomatic Menkes disease patients is less clear.
Genetic counseling is recommended for the parents and families of affected children for a proper understanding of recurrence risk.
One-time adeno-associated viral gene therapy in combination with subcutaneous CuHis injections represents a promising treatment approach in development for subjects with Menkes disease.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site:
https://clinicaltrials.gov/ct2/results?cond=Menkes+Disease&term=&cntry=&state=&city=&dist=
A Menkes Disease Clinic was established in Fall 2019 at Nationwide Childrenโs Hospital in Columbus, OH in affiliation with the Ohio State College of Medicine:
https://www.nationwidechildrens.org/find-a-doctor/profiles/stephen-g-kaler
Some current clinical trials also are posted on the following page on the NORD website:
https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/
For information about clinical trials sponsored by private sources, contact:
https://www.centerwatch.com/
For more information about clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/
TEXTBOOKS
Menkes JH. Menkes Disease. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:470.
Menkes JH, Sarnat HB, eds. Textbook of Child Neurology. 7th ed. Williams & Wilkins. Baltimore, MD; 2006:115-117.
Kaler SG: Menkes Disease. In: Advances in Pediatrics, Volume 41 (Barness LA, ed.), C.V. Mosby 1994:263-304.
JOURNAL ARTICLES
Vairo FPE, Chwal BC, Perini S, Ferreira MAP, De freitas lopes AC, Saute JAM. A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. Mol Genet Metab. 2019;126(1):6-13.
Kaler SG: The neurology of ATP7A copper transporter disease: emerging concepts and future trends. Nature Reviews Neurology 2011; 7:15-29.
Tรผmer Z, Mรธller LB. Menkes disease. Eur J Hum Genet. 2010;18(5):511-8.
Kaler SG, Holmes CS, Goldstein DS, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008;358:605-14.
Shim H, Harris ZL. Genetic defects in copper metabolism. J Nutr. 2003;133(5 Suppl 1):1527S-31S.
Mercer JF, Llanos RM. Molecular and cellular aspects of copper transport in developing mammals. J Nutr. 2003;133(5 Suppl 1):1481S-84S.
Llanos RM, Mercer JF. The molecular basis of copper homeostasis copper-related disorders. DNA Cell Biol. 2002;21:259-70.
Andrews NC. Metal transporters and disease. Curr Opin Chem Biol. 2002;6:181-86.
Strausak D, Mercer JF, Dieter HH, et al. Copper in disorders with neurological symptoms: Alzheimerโs, Menkes, and Wilson diseases. Brain Res Bull. 2001;55:175-85.
Mercer JF. The molecular basis of copper-transport diseases. Trends Mol Med. 2001;7:64-69.
Harris ED. Cellular copper transport and metabolism. Annu Rev Nutr. 2000;20:291-310.
Menkes JH. Menkes disease and Wilson disease: two sides of the same copper coin. Part II: Wilson disease. Eur J Paediatr Neurol. 1999;3:245-53.
Menkes JH. Menkes disease and Wilson disease: two sides of the same copper coin. Part I: Menkes disease. Eur J Paediatr Neurol. 1999;3:145-58.
Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol. 1998;1:85-98.
Kaler SG: Diagnosis and therapy of Menkes disease, a genetic form of copper
deficiency. Am J Clin Nutr. 1998; 67:S1029-1034.
Kaler SG: Menkes disease mutations and response to early copper histidine treatment. Nature Genetics 1996; 13: 21-22.
Kaler SG, Gallo LK, Proud VK, Percy AK, Mark Y, Segal NA, Goldstein DS, Holmes CS, Gahl WA: Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nature Genetics 1994; 8:195-202.
INTERNET
Kaler SG. ATP7A-Related Copper Transport Disorders. 2003 May 9 [Updated 2016 Aug 18]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviewsยฎ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1413/ Accessed March 3, 2020.
Online Mendelian Inheritance in Man (OMIM). Menkes Disease. Updated 12/20/2019. https://www.omim.org/entry/309400 Accessed March 3, 2020.
NINDS Menkes Disease Information Page. Reviewed 2019-03-27. https://www.ninds.nih.gov/Disorders/All-Disorders/Menkes-Disease-Information-Page Accessed March 3, 2020.
Chang CH. Menkes Disease.Medscape. Last Updated: December 10, 2019. 13pp.
www.emedicine.com/neuro/topic569.htm Accessed March 3, 2020.
NORD strives to open new assistance programs as funding allows. If we donโt have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.
Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORDโs mission.
Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.
Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/The information provided on this page is for informational purposes only. The National Organization for Rare Disorders (NORD) does not endorse the information presented. The content has been gathered in partnership with the MONDO Disease Ontology. Please consult with a healthcare professional for medical advice and treatment.
The Genetic and Rare Diseases Information Center (GARD) has information and resources for patients, caregivers, and families that may be helpful before and after diagnosis of this condition. GARD is a program of the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
View reportOrphanet has a summary about this condition that may include information on the diagnosis, care, and treatment as well as other resources. Some of the information and resources are available in languages other than English. The summary may include medical terms, so we encourage you to share and discuss this information with your doctor. Orphanet is the French National Institute for Health and Medical Research and the Health Programme of the European Union.
View reportOnline Mendelian Inheritance In Man (OMIM) has a summary of published research about this condition and includes references from the medical literature. The summary contains medical and scientific terms, so we encourage you to share and discuss this information with your doctor. OMIM is authored and edited at the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine.
View report
Your donation will help more than 30 million Americans with a rare disease navigate their diagnosis, receive financial assistance, and access the care and support they deserve. Make your tax-deductible gift today!